Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).

R. Hehlmann,Michael Lauseker,Susanne Saussele,Markus Pfirrmann,Andreas Neubauer,Stefan W. Krause,Dieter K. Hossfeld,Christoph Nerl,Gabriela M. Baerlocher,Dominik Heim,Hans Jochem Kolb,Ulrike Proetel,K. Kohlbrenner,A Gratwohl,Andreas Burchert,A. Voskanyan,S. Rinaldetti,Andreas Hochhaus,Joerg Hasford,Sakk

Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).

2017

7049Background: It is unclear whether IM 400 mg is the optimum choice for the successful treatment of CML. Treatment optimization was therefore attempted. Methods: From July 2002 to March 2012, 155...

Keywords:

Physical therapy
Cancer research
Imatinib
Myeloid leukemia
Medicine
Gastroenterology
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations